KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review
详细信息 查看全文
- 作者：Hironobu Shigaki MD (1)
Yoshifumi Baba MD ; PhD (1)
Masayuki Watanabe MD ; PhD ; FACS (1)
Keisuke Miyake MSc (1)
Asuka Murata MD (1)
Shiro Iwagami MD ; PhD (1)
Takatsugu Ishimoto MD ; PhD (1)
Masaaki Iwatsuki MD ; PhD (1)
Naoya Yoshida MD ; PhD (1)
Hideo Baba MD ; PhD ; FACS (1) - 刊名：Annals of Surgical Oncology
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：20
- 期：3-supp
- 页码：485-491
- 全文大小：659 KB
- 参考文献：1. Enzinger PC, Mayer RJ. Esophageal cancer. / N Engl J Med. 2003;349:2241-2. 10.1056/NEJMra035010" target="_blank" title="It opens in new window">CrossRef
2. Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. / J Clin Oncol. 2011;29:4709-4. 10.1200/JCO.2011.36.7599" target="_blank" title="It opens in new window">CrossRef
3. Stahl M. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer? / Ann Oncol. 2010;21(Suppl 7):vii283-.
4. Chen WH, Chao YK, Chang HK, Tseng CK, Wu YC, Liu YH, et al. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma. / Dis Esophagus. 2012;25:250-. 10.1111/j.1442-2050.2011.01243.x" target="_blank" title="It opens in new window">CrossRef
5. Pantling AZ, Gossage JA, Mamidanna R, Newman G, Robinson A, Manifold DK, et al. Outcomes from chemoradiotherapy for patients with esophageal cancer. / Dis Esophagus. 2011;24:172-. 10.1111/j.1442-2050.2010.01121.x" target="_blank" title="It opens in new window">CrossRef
6. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? / Nat Rev Clin Oncol. 2011;9:87-7. 10.1038/nrclinonc.2011.164" target="_blank" title="It opens in new window">CrossRef
7. McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. / Curr Oncol Rep. 2012;14:342-. 10.1007/s11912-012-0239-7" target="_blank" title="It opens in new window">CrossRef
8. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. / Ann Oncol. 2009;20:1667-3. 10.1093/annonc/mdp069" target="_blank" title="It opens in new window">CrossRef
9. Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. / Cancer. 2011;117:1409-4. 10.1002/cncr.25602" target="_blank" title="It opens in new window">CrossRef
10. Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI, Rice TW. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. / Invest New Drugs. 2010;30:1684-. 10.1007/s10637-011-9736-z" target="_blank" title="It opens in new window">CrossRef
11. Han W, Lo HW. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. / Cancer Lett. 2012;318:124-4. 10.1016/j.canlet.2012.01.011" target="_blank" title="It opens in new window">CrossRef
12. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. / Nat Rev Cancer. 2009;9:489-9. 10.1038/nrc2645" target="_blank" title="It opens in new window">CrossRef
13. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. / Cancer Cell. 2004;6:313-. 10.1016/j.ccr.2004.09.022" target="_blank" title="It opens in new window">CrossRef
14. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. / Lancet Oncol. 2011;12:594-03. 10.1016/S1470-2045(10)70209-6" target="_blank" title="It opens in new window">CrossRef
15. Ma H, Xue Y, Li C, Zhang J, Ren Z. A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma. Chinese-German. / J Clin Oncol. 2011;10:497-01.
16. Liu QW, Fu JH, Luo KJ, Yang HX, Wang JY, Hu Y, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. / Dis Esophagus. 2011. doi:10.1111/j.1442-2050.2010.01155.x . [Epub ahead of print].
17. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. / Cancer Res. 1991;51:4102-.
18. Victor T, Du Toit R, Jordaan AM, Bester AJ, van Helden PD. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. / Cancer Res. 1990;50:4911-.
19. Hollstein MC, Smits AM, Galiana C, Yamasaki H, Bos JL, Mandard A, et al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. / Cancer Res. 1988;48:5119-3.
20. Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, Jang J, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. / PLoS One. 2012;7:e41655. 10.1371/journal.pone.0041655" target="_blank" title="It opens in new window">CrossRef
21. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. / Hum Mutat. 2002;19:479-5. 10.1002/humu.10078" target="_blank" title="It opens in new window">CrossRef
22. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. / J Mol Diagn. 2005;7:413-1. 10.1016/S1525-1578(10)60571-5" target="_blank" title="It opens in new window">CrossRef
23. Shen S, Qin D. Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. / Diagn Pathol. 2012;7:56. 10.1186/1746-1596-7-56" target="_blank" title="It opens in new window">CrossRef
24. Chen DC, Saarela J, Nuotio I, Jokiaho A, Peltonen L, Palotie A. Comparison of GenFlex Tag array and Pyrosequencing in SNP genotyping. / J Mol Diagn. 2003;5:243-. 10.1016/S1525-1578(10)60481-3" target="_blank" title="It opens in new window">CrossRef
25. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. / Clin Cancer Res. 2012;18:4753-3. 10.1158/1078-0432.CCR-11-3210" target="_blank" title="It opens in new window">CrossRef
26. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. / Clin Cancer Res. 2009;15:7322-. 10.1158/1078-0432.CCR-09-1570" target="_blank" title="It opens in new window">CrossRef
27. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. / Ann Surg Oncol. 2010;17:1721-. 10.1245/s10434-010-1024-1" target="_blank" title="It opens in new window">CrossRef
28. Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, et al. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. / PLoS One. 2012;7:e41347.
29. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. / Cancer Res. 2011;71:5535-5. 10.1158/0008-5472.CAN-10-4351" target="_blank" title="It opens in new window">CrossRef
30. Ozawa S, Tachimori Y, Baba H, Fujishiro M, Matsubara H, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2004. / Esophagus. 2012;9:75-8. 10.1007/s10388-012-0327-7" target="_blank" title="It opens in new window">CrossRef
31. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? / Nat Rev Clin Oncol. 2009;6:528-4. 10.1038/nrclinonc.2009.106" target="_blank" title="It opens in new window">CrossRef
32. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. / J Natl Cancer Inst. 2001;93:1062-4. 10.1093/jnci/93.14.1062" target="_blank" title="It opens in new window">CrossRef
33. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. / Nature. 2002;417:949-4. 10.1038/nature00766" target="_blank" title="It opens in new window">CrossRef
34. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. / Clin Cancer Res. 2012;18:890-00. 10.1158/1078-0432.CCR-11-2246" target="_blank" title="It opens in new window">CrossRef
35. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. / Gut. 2009;58:90-. 10.1136/gut.2008.155473" target="_blank" title="It opens in new window">CrossRef
36. Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. / Cancer. 2012. doi:10.1002/cncr.27782 . [Epub ahead of print].
37. Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, et al. Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. / Ann Surg Oncol. 2012;19:4314-1. 10.1245/s10434-012-2457-5" target="_blank" title="It opens in new window">CrossRef - 作者单位：Hironobu Shigaki MD (1)
Yoshifumi Baba MD, PhD (1)
Masayuki Watanabe MD, PhD, FACS (1)
Keisuke Miyake MSc (1)
Asuka Murata MD (1)
Shiro Iwagami MD, PhD (1)
Takatsugu Ishimoto MD, PhD (1)
Masaaki Iwatsuki MD, PhD (1)
Naoya Yoshida MD, PhD (1)
Hideo Baba MD, PhD, FACS (1)
1. Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan - ISSN：1534-4681
文摘
Background Epidermal growth factor receptor (EGFR) signaling is one of the most promising targets for molecular-targeted therapies in esophageal squamous cell carcinoma (ESCC). Thus, the molecular diagnosis of KRAS and BRAF mutations is clinically important in therapeutic decision making. However, the frequency of KRAS and BRAF mutations in ESCCs remains inconclusive because of the limited sample sizes of previous studies (all N?≤?0). Pyrosequencing is a nonelectrophoretic nucleotide extension sequencing technology that can be used for mutation testing. Methods The frequency of KRAS and BRAF mutations was examined using a nonbiased database of 203 resected ESCCs and a high-throughput pyrosequencing assay. Results The validity of the KRAS pyrosequencing method was initially demonstrated by detection of all 4 types of KRAS mutations [c.35G>T (codon 12 GGT>GTT), c.35G>A (codon 12 GGT>GAT), c.34G>T (codon 12 GGT>TGT), c.38G>A mutation (codon 13 GGC>GAC)], which had been previously diagnosed using Scorpion-ARMS technology, in 9 colon cancer tissues (9 of 9; 100?%). Similar results were demonstrated for BRAF mutational status in 3 colon cancer cell lines (HCT116, Colo201, and HT29), which were validated by Sanger dideoxy sequencing. Subsequently, the KRAS mutation was found to be extremely rare (1 of 203; 0.5?%), and the BRAF mutation was absent (0 of 203; 0?%), in the dataset of 203 ESCCs. Conclusions These results suggest that KRAS and BRAF mutations play a limited role in the development of ESCC and that mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in ESCC.